Top Page
Chaoju Eye Care Holdings Ltd.
(2219)
Chaoju Eye Care Holdings Ltd. (2219) vs. iShares MSCI Hong Kong ETF (EWH)
Chaoju Eye Care Holdings Ltd. Business Overview & Revenue Model
Chaoju Eye Care Holdings Ltd. Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.41B | 1.37B | 990.04M | 997.79M | 794.28M |
| Gross Profit | 611.30M | 621.13M | 434.70M | 448.67M | 349.48M |
| EBITDA | 335.37M | 434.82M | 234.40M | 304.65M | 259.78M |
| Net Income | 195.08M | 228.91M | 187.75M | 161.75M | 124.14M |
Balance Sheet | |||||
| Total Assets | 2.88B | 2.92B | 2.72B | 2.51B | 1.09B |
| Cash, Cash Equivalents and Short-Term Investments | 1.53B | 1.55B | 1.68B | 1.78B | 415.97M |
| Total Debt | 218.01M | 200.80M | 196.16M | 178.65M | 142.36M |
| Total Liabilities | 554.76M | 544.38M | 424.68M | 378.11M | 325.48M |
| Stockholders Equity | 2.32B | 2.36B | 2.27B | 2.11B | 737.25M |
Cash Flow | |||||
| Free Cash Flow | 354.36M | 286.02M | 148.29M | 189.18M | 196.16M |
| Operating Cash Flow | 354.36M | 372.57M | 273.41M | 249.39M | 248.75M |
| Investing Cash Flow | 245.36M | -654.10M | -464.77M | -578.51M | -35.45M |
| Financing Cash Flow | -292.30M | -204.01M | -165.43M | 1.19B | -39.61M |
Chaoju Eye Care Holdings Ltd. Technical Analysis
Chaoju Eye Care Holdings Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | HK$2.16B | 9.78 | 8.35% | 2.99% | 0.61% | -15.89% | |
69 Neutral | HK$962.52M | 12.07 | 7.39% | 2.76% | 0.20% | -36.95% | |
68 Neutral | HK$1.75B | 5.33 | 24.13% | 4.09% | -3.85% | -19.28% | |
61 Neutral | HK$1.69B | ― | -6.55% | 0.48% | 0.04% | -4.88% | |
60 Neutral | HK$17.07B | 6.10 | -7.44% | 2.88% | 11.55% | -28.15% | |
57 Neutral | HK$635.35M | 38.23 | 1.07% | 5.08% | -1.20% | -87.51% | |
52 Neutral | HK$2.26B | 33.92 | -7.51% | 1.11% | -0.56% | -323.09% |
Chaoju Eye Care Holdings Ltd. Corporate Events
Chaoju Eye Care Holdings Ltd. announced the acquisition of equity interests in Ningbo Boshi Eye Hospital Co., Ltd. and Wuzhong Yunshikang Eye Hospital Co., Ltd. These strategic acquisitions aim to integrate medical resources, optimize hospital operations, and expand the company’s service network in Zhejiang and Ningxia. By consolidating these entities into its financial statements, Chaoju Eye Care seeks to strengthen its market position and mitigate risks, aligning with its strategic growth plans.
Chaoju Eye Care Holdings Ltd. has amended the terms of reference for its Nomination Committee to enhance corporate governance and protect shareholder interests. The committee, composed mainly of independent non-executive directors, is tasked with recommending candidates for directors and senior management, ensuring diversity and adherence to regulatory standards.
Chaoju Eye Care Holdings Limited has announced a change in its Nomination Committee to comply with the revised Corporate Governance Code effective from July 1, 2025. Ms. GUO Hongyan, an independent non-executive Director, has been appointed to the committee, which now includes three independent non-executive Directors and one executive Director, ensuring gender diversity.
Chaoju Eye Care Holdings Ltd. has announced the composition of its board of directors, detailing the roles and functions of each member. The board comprises executive, non-executive, and independent non-executive directors, with various members assigned to four key committees: Audit, Remuneration, Nomination, and Environmental, Social, and Governance. This announcement highlights the company’s structured governance approach, which could impact its strategic decision-making and stakeholder engagement.
Chaoju Eye Care Holdings Ltd. has announced a new subscription of structured deposit products through its subsidiary, Chaoju Medical Technology, totaling RMB100 million with the Bank of China. This move is part of a series of transactions with the bank, aggregating previous subscriptions to exceed a 5% but less than 25% threshold, thereby classifying them as discloseable transactions under Hong Kong’s Listing Rules. The subscriptions are funded by surplus cash, indicating a strategic financial management approach without tapping into global offering proceeds.
Chaoju Eye Care Holdings Ltd. held its Annual General Meeting on June 6, 2025, where all proposed resolutions were passed with significant shareholder support. Key resolutions included the adoption of financial statements, declaration of a final dividend, re-election of directors, and re-appointment of auditors, reflecting strong governance and shareholder confidence.
Chaoju Eye Care Holdings Ltd. announced that two of its hospitals, Inner Mongolia Chaoju Eye Hospital and Baotou Chaoju Eye Hospital, have been rated as Grade 3A specialized hospitals, reflecting their excellence in medical services, technology, and research capabilities. This achievement is expected to enhance the hospitals’ reputation, attract more resources, and contribute to local healthcare development. Additionally, Chifeng Chaoju Eye Hospital received a Grade 3B rating, indicating progress in the company’s service network. Chaoju Eye Care plans to leverage these ratings to further invest in medical technology and service quality, aiming to improve patient experience and expand the reach of quality ophthalmic healthcare.
Chaoju Eye Care Holdings Ltd. has announced its upcoming Annual General Meeting (AGM) scheduled for June 6, 2025, in Beijing, China. Key agenda items include the adoption of financial statements, declaration of a final dividend, re-election of directors, and re-appointment of auditors. The company also seeks approval to empower its directors to issue additional shares, which could potentially impact its market operations and shareholder value.